Dana Akhmentayeva

Dr. Dana Akhmentayeva

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2025 in Diseases
Verified
Journal Article
Open access
PDF file
AMAisulu Mussagaliyeva
Aisulu Mussagaliyeva
Sholpan Bolatovna ZhangelovaSholpan Bolatovna Zhangelova
Sholpan Bolatovna Zhangelova
Laura Bakhytzhanovna DanyarovaLaura Bakhytzhanovna Danyarova
Laura Bakhytzhanovna Danyarova
Nurmukhammad Friba NasrullakyzyNurmukhammad Friba Nasrullakyzy
Nurmukhammad Friba Nasrullakyzy
Dina Amangeldinovna KapsultanovaDina Amangeldinovna Kapsultanova
Dina Amangeldinovna Kapsultanova
DADana Akhmentayeva
Dana Akhmentayeva
Background: Coronary artery bypass grafting (CABG) remains a standard revascularization strategy for patients with advanced coronary artery disease (CAD). However, a considerable proportion of patients experience recurrent ischemia requiring repeat revascularization. Residual platelet reactivity (RPR) and dyslipidemia are recognized as key factors contributing to graft failure and disease progression. Methods: This observational study was conducted at a tertiary cardiology center in Kazakhstan. A total of 195 post-CABG patients who underwent repeat coronary angiography between 2023 and 2024 recruitment period for recurrent ischemic symptoms within 6–36 months after surgery were included. Clinical characteristics, comorbidities, lipid profiles, and antiplatelet response were analyzed. RPR was measured using the VerifyNow P2Y12 assay when available. Dyslipidemia was defined according to the 2019 and 2021 European guidelines. Results: Elevated RPR was identified in 45% of patients (n = 90) despite dual antiplatelet therapy (p < 0.01). Poor lipid control was frequent among those who underwent repeat percutaneous coronary intervention (PCI), particularly elevated levels of low-density lipoprotein cholesterol (LDL-C) and total cholesterol (p < 0.05). Both elevated RPR and dyslipidemia were independently associated with native coronary disease progression and graft failure (RPR: OR = 2.8; 95% CI 1.4–5.6; p = 0.003; dyslipidemia: OR = 2.2; 95% CI 1.1–4.3; p = 0.02). The use of ezetimibe was independently associated with a significantly lower risk of repeat stenting (OR = 0.12; 95% CI 0.02–0.75; p = 0.023). Smokers were younger, had lower blood pressure, and less frequently presented with diabetes or chronic kidney disease, demonstrating a pattern consistent with the “smoker’s paradox.” Conclusions: Residual platelet reactivity and dyslipidemia are common and clinically relevant predictors of repeat revascularization after CABG. Optimization of antiplatelet and lipid-lowering therapy should be prioritized in secondary prevention for this high-risk population. These findings are particularly important in Kazakhstan, where post-CABG management strategies warrant further improvement.

29 May 2026 in Diseases
Verified
Journal Article
Open access
PDF file
Sholpan Bolatovna ZhangelovaSholpan Bolatovna Zhangelova
Sholpan Bolatovna Zhangelova
OSOrazbek Sakhov
Orazbek Sakhov
LALyazat Abisheva
Lyazat Abisheva
DPDmitriy Polyakov
Dmitriy Polyakov
FRFarida Rustamova
Farida Rustamova
Nurmukhammad Friba NasrullakyzyNurmukhammad Friba Nasrullakyzy
Nurmukhammad Friba Nasrullakyzy
Background: Optimal platelet inhibition is essential for minimizing both thrombotic and hemorrhagic complications in patients with coronary artery disease (CAD). Although high on-treatment platelet reactivity (HPR) has been consistently associated with adverse clinical outcomes, the relationship between platelet reactivity—measured as P2Y12 reaction units (PRU)—and cardiovascular mortality remains incompletely characterized. In particular, potential non-linear associations have not been adequately explored. Objective: We aimed to investigate the association between PRU and cardiovascular mortality in patients with CAD, with a specific focus on identifying potential non-linear relationships. Methods: We conducted a retrospective observational cohort study including 1000 patients with angiographically confirmed CAD treated at a tertiary cardiology center in Almaty, Kazakhstan, between 2024 and 2025. Platelet reactivity was assessed using the VerifyNow P2Y12 assay. Multivariable logistic regression models were used to identify independent predictors of cardiovascular mortality. To assess potential non-linear associations between PRU and mortality, restricted cubic spline regression was applied with predefined knot placement. Model performance was evaluated in terms of discrimination (C-statistic) and calibration (Hosmer-Lemeshow goodness-of-fit test). Results: In conventional linear regression models, PRU was not independently associated with cardiovascular mortality (odds ratio [OR] ~1.00; p > 0.05). However, spline-based analyses demonstrated a statistically significant non-linear (U-shaped) relationship between PRU and mortality risk (p for non-linearity = X). Both low and high PRU values were associated with increased mortality, whereas intermediate PRU levels corresponded to the lowest observed risk. Additional independent predictors of mortality included advanced age, diabetes mellitus, and elevated inflammatory markers. Conclusions: Our findings reveal a significant non-linear association between platelet reactivity and cardiovascular mortality in patients with CAD. Both insufficient and excessive platelet inhibition appear to confer increased risk, suggesting that optimal PRU targets may lie within an intermediate therapeutic range. These results support a paradigm shift toward more individualized antiplatelet therapy strategies guided by platelet function testing.

30 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
AMAisulu Mussagaliyeva
Aisulu Mussagaliyeva
Sholpan Bolatovna ZhangelovaSholpan Bolatovna Zhangelova
Sholpan Bolatovna Zhangelova
Laura Bakhytzhanovna DanyarovaLaura Bakhytzhanovna Danyarova
Laura Bakhytzhanovna Danyarova
Nurmukhammad Friba NasrullakyzyNurmukhammad Friba Nasrullakyzy
Nurmukhammad Friba Nasrullakyzy
Dina Amangeldinovna KapsultanovaDina Amangeldinovna Kapsultanova
Dina Amangeldinovna Kapsultanova
DADana Akhmentayeva
Dana Akhmentayeva
Background: Coronary artery bypass grafting (CABG) is a standard treatment for ad-vanced coronary artery disease (CAD). Despite its effectiveness, many patients devel-op recurrent ischemia requiring repeat revascularization. Residual platelet reactivity (RPR) and dyslipidemia are considered important contributors to graft failure and dis-ease progression. This study investigated the association of RPR and dyslipidemia with repeat revascularization in post-CABG patients. Methods: A observational cohort study was performed at a tertiary cardiology center in Kazakhstan. A total of 200 patients with prior CABG who underwent repeat coro-nary angiography between 2023 and 2024 for recurrent ischemic symptoms were in-cluded. Clinical data, comorbidities, lipid profiles, and antiplatelet response were ana-lyzed. RPR was measured with the VerifyNow P2Y12 assay where available. Dyslipidemia was defined according to current European guidelines, 2019/2021. Results: Elevated RPR was found in 45% (n = 90) of patients despite dual antiplatelet therapy. Poor lipid control, especially increased low-density lipoprotein cholesterol (LDL-C) and total cholesterol was common among patients undergoing repeat percu-taneous coronary intervention (PCI). Both RPR and dyslipidemia were independently associated with native coronary disease progression and graft failure. Conclusions: RPR and dyslipidemia are frequent and clinically relevant predictors of repeat revascularization after CABG. Optimizing antiplatelet and lipid-lowering ther-apy should be a priority in secondary prevention for this high-risk group. These results are particularly important in the Central Asian setting, where post-CABG management strategies require further improvement.

12 January 2026 in Diseases
Verified
Journal Article
Open access
PDF file
Dina Amangeldinovna KapsultanovaDina Amangeldinovna Kapsultanova
Dina Amangeldinovna Kapsultanova
Sholpan Bolatovna ZhangelovaSholpan Bolatovna Zhangelova
Sholpan Bolatovna Zhangelova
Nurmukhammad Friba NasrullakyzyNurmukhammad Friba Nasrullakyzy
Nurmukhammad Friba Nasrullakyzy
Zulfiya MakashevaZulfiya Makasheva
Zulfiya Makasheva
OSOrazbek Sakhov
Orazbek Sakhov
BABotakoz Kalenovna Aubakirova
Botakoz Kalenovna Aubakirova
Background: High residual platelet reactivity (HRPR) and persistent dyslipidemia remain important unmet needs in cardiovascular risk management, particularly in patients undergoing coronary revascularization. Despite intensive lipid-lowering and antiplatelet therapy, a substantial proportion of patients fail to reach recommended low-density lipoprotein cholesterol (LDL-C) targets or exhibit inadequate platelet inhibition. Inclisiran, a PCSK9-targeting small interfering RNA, represents an emerging approach for long-term LDL-C reduction. Methods: A narrative review of the literature published between 2009 and 2025 was performed using PubMed, Scopus, Web of Science, and MEDLINE. Studies evaluating the addition of inclisiran to standard lipid-lowering therapy in patients with dyslipidemia and HRPR, assessed using the VerifyNow assay, were included. Illustrative clinical cases from Kazakhstan were analyzed to demonstrate real-world changes in LDL-C levels and platelet reactivity following insufficient response to conventional treatment. The review had a descriptive design. Results: Available evidence indicates that a significant proportion of high- and very-high-risk patients do not achieve LDL-C targets or are unable to tolerate high-intensity statin therapy. Inclisiran consistently induces sustained reductions in LDL-C and circulating PCSK9 levels. Emerging data suggest a potential indirect modulation of platelet reactivity associated with intensive lipid lowering. In patients at extreme cardiovascular risk—including those after coronary artery bypass grafting (CABG) and with long-standing multivessel coronary artery disease—inclisiran therapy was associated with marked LDL-C reduction and a trend toward normalization of platelet reactivity. Conclusions: Assessment of platelet function using the VerifyNow assay may improve identification of residual thrombotic risk in patients with advanced atherosclerotic disease. Inclisiran appears to be a promising adjunctive therapy for dyslipidemic patients with persistently elevated cardiovascular risk and HRPR despite standard treatment. Further prospective studies are warranted to clarify the relationship between intensive LDL-C lowering, platelet reactivity, and clinical outcomes, and to optimize integrated lipid-lowering and antiplatelet strategies.

29 April 2025 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
GAG. P. Arutyunov
G. P. Arutyunov
ETE. I. Tarlovskaya
E. I. Tarlovskaya
AAAlexander Arutyunov
Alexander Arutyunov
TBT. I. Batluk
T. I. Batluk
NKN. A. Koziolova
N. A. Koziolova
ЯХЯ. Б. Ховаева
Я. Б. Ховаева
Aim. To study real-world data on managing patients with coronary artery disease (CAD) and multifocal atherosclerosis (MFA) for 12 months by outpatient cardiologists.Material and methods. KAMMA is a real-world registry organized by the Eurasian Association of Therapists. The main branch included men and women over 18 years of age with confirmed atherosclerosis in two or more arterial systems and one or more risk factors for atherosclerosis. The start date for patient recruitment was February 1, 2022 and the end date was November 27, 2022. The design included 3 following visits: 1 — baseline, 2 — after 6 months, 3 — after 12 months. Twentyeight research centers were located in 7 federal districts of the Russian Federation, as well as in the Republics of Kazakhstan, Uzbekistan and Belarus.Results. A patient population (n=2905) was formed, all of whom had verified CAD. The mean age was 66,0 [59,0; 72,0] years (men — 60,3%). Low-density lipoprotein cholesterol decreased by 20,4% over 12 months, while non-high-density lipoprotein cholesterol — by 12,7%. Over 12 months, lipid-lowering therapy did not undergo significant changes. Statin monotherapy was maintained in 83%, of which only 53,7% of patients received high-dose therapy. Combined statin+ezetimibe therapy was used in 12,4%, while statin+ezetimibe+PCSK9 inhibitor — in 4,6%. During the 1-year follow-up, antithrombotic therapy was not enhanced. Low prescription rate of combination therapy with antiplatelet agents (15,7%) and low-dose rivaroxaban and acetylsalicylic acid (7,9%) remained. By the follow-up end, a high incidence of major adverse cardiovascular events (8,8%) was registered in patients included in the KAMMA registry.Conclusion. Despite the fact that patients with MFA have a very high cardiovascular risk, routine management of these patients is characterized by high clinical inertia. During the 1-year follow-up, lipid-lowering and antithrombotic therapy was not properly strengthened, due to which the target levels of key lipid profile parameters were not achieved and a high rate of major adverse cardiovascular events was observed in patients included in the registry.

24 September 2024 in Vestnik
Verified
Journal Article
Closed access
ШОШ.о. Оспанова
Ш.о. Оспанова
Akhmetzhan SugraliyevAkhmetzhan Sugraliyev
Akhmetzhan Sugraliyev
ТМТ.а. Муминов
Т.а. Муминов
ГАГ.т. Аймаханова
Г.т. Аймаханова
ГДГ.м. Дабылова
Г.м. Дабылова
ИБИ.ж. Байболсынова
И.ж. Байболсынова
Настоящая обзорная статья посвящена анализу текущих данных по респираторным проявлениям постковидного синдрома, представляющими собой одно из значимых последствий перенесенной COVID-19. В работе рассматриваются основные клинические проявления, патогенетические механизмы и подходы к лечению постковидного синдрома. На основе анализа современной литературы выделены ключевые направления для дальнейших исследований и даны рекомендации для клинической практики. Полученные данные подчеркивают важность комплексного подхода к диагностике и лечению данного состояния, что может значительно улучшить качество жизни пациентов. Бұл шолу мақаласы COVID-19 инфекциясынан кейінгі дамитын маңызды салдарының бірі болып табылатын постковид синдромының респираторлы көріністері бойынша ағымдағы деректердің талдауына арналған. Мұнда постковид синдромының негізгі клиникалық көріністері, патогенетикалық механизмдері мен емдеу тәсілдері қарастырылады. Қазіргі заманауи әдебиеттерді талдау негізінде әрі қарай зерттеуде басты бағыттар анықталынған және клиникалық тәжірибе үшін ұсыныстар берілген. Алынған нәтижелер осы жағдайдың диагностикасын және емін кешенді түрде қарастырудың маңыздылығын көрсетеді, ал ол науқастардың өмір сүру сапасын едәуір жақсартатыны анық. This review article is dedicated to analyzing current data on respiratory manifestations of post-COVID syndrome, which represent one of the significant consequences of COVID-19. The paper discusses the main clinical manifestations, pathogenetic mechanisms, and approaches to treating post-COVID syndrome. Based on the analysis of modern literature, key directions for further research are highlighted, and recommendations for clinical practice are provided. The findings emphasize the importance of a comprehensive approach to the diagnosis and treatment of this condition, which can significantly improve patients' quality of life.